Sign up to save your podcasts
Or
Share European Lung Cancer Conference (ELCC) 2025 Highlights: KEYNOTE-799, LAURA, MARIPOSA, KRYSTAL-7
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
European Lung Cancer Conference (ELCC) 2025 Highlights: KEYNOTE-799, LAURA, MARIPOSA, KRYSTAL-7
Welcome back to the Oncology Brothers podcast! In this episode, Drs. Rahul and Rohit Gosain are joined by Dr. Joshua Sabari, a thoracic medical oncologist from NYU, to discuss the latest findings from the European Lung Cancer Conference (ELCC) 2025.
We dived into several key studies that are shaping the future of lung cancer treatment, including:
• KEYNOTE-799: Exploring the combination of concurrent chemotherapy and radiation with the PD-1 inhibitor pembrolizumab for unresectable non-small cell lung cancer (NSCLC).
• LAURA: The impact of osimertinib in patients with EGFR mutations post-chemoradiation therapy.
• MARIPOSA: The promising results of amivantamab and lisertinib in the metastatic setting for EGFR-mutated NSCLC.
• KRYSTAL-7: Investigating the use of KRAS G12C inhibitors in frontline therapy.
Join us as we discuss the implications of these studies, the importance of next-generation sequencing (NGS), and how to manage side effects associated with these new therapies.
YouTube: https://youtu.be/akoXXAUEl_8
Follow us on social media:
• X/Twitter: https://twitter.com/oncbrothers
• Instagram: https://www.instagram.com/oncbrothers
• Website: https://oncbrothers.com/
Don't forget to like, subscribe, and hit the notification bell for more updates on the latest in oncology!
#Oncology #LungCancer #ELCC2025 #EGFR #KRAS #CancerResearch #Podcast
View all episodes
By Oncology Brothers
4.8
3939 ratings
Welcome back to the Oncology Brothers podcast! In this episode, Drs. Rahul and Rohit Gosain are joined by Dr. Joshua Sabari, a thoracic medical oncologist from NYU, to discuss the latest findings from the European Lung Cancer Conference (ELCC) 2025.
We dived into several key studies that are shaping the future of lung cancer treatment, including:
• KEYNOTE-799: Exploring the combination of concurrent chemotherapy and radiation with the PD-1 inhibitor pembrolizumab for unresectable non-small cell lung cancer (NSCLC).
• LAURA: The impact of osimertinib in patients with EGFR mutations post-chemoradiation therapy.
• MARIPOSA: The promising results of amivantamab and lisertinib in the metastatic setting for EGFR-mutated NSCLC.
• KRYSTAL-7: Investigating the use of KRAS G12C inhibitors in frontline therapy.
Join us as we discuss the implications of these studies, the importance of next-generation sequencing (NGS), and how to manage side effects associated with these new therapies.
YouTube: https://youtu.be/akoXXAUEl_8
Follow us on social media:
• X/Twitter: https://twitter.com/oncbrothers
• Instagram: https://www.instagram.com/oncbrothers
• Website: https://oncbrothers.com/
Don't forget to like, subscribe, and hit the notification bell for more updates on the latest in oncology!
#Oncology #LungCancer #ELCC2025 #EGFR #KRAS #CancerResearch #Podcast
More shows like Oncology Brothers: Practice-Changing Cancer Discussions
View all
NEJM This Week
324 Listeners
Journal of Clinical Oncology (JCO) Podcast
41 Listeners
Research To Practice | Oncology Videos
111 Listeners
JAMA Clinical Reviews
507 Listeners
ASCO Daily News
61 Listeners
Core IM | Internal Medicine Podcast
1,120 Listeners
OncoPharm
182 Listeners
ASCO Guidelines
45 Listeners
OncLive® On Air
23 Listeners
Harrison's PodClass: Internal Medicine Cases and Board Prep
362 Listeners
Lung Cancer Considered
28 Listeners
The Passive Income MD Podcast
277 Listeners
Oncology Today with Dr Neil Love
60 Listeners
Two Onc Docs
181 Listeners
Blood Cancer Talks
48 Listeners